A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis | Zendy

Philip N. Newsome | Zendy; Kristine Buchholtz | Zendy; Kenneth Cusi | Zendy; Martin Linder | Zendy; Takeshi Okanoue | Zendy; Vlad Ratziu | Zendy; Arun J. Sanyal | Zendy; AnneSophie Sejling | Zendy; Stephen A. Harrison | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Author(s) -

Philip N. Newsome,

Kristine Buchholtz,

Kenneth Cusi,

Martin Linder,

Takeshi Okanoue,

Vlad Ratziu,

Arun J. Sanyal,

AnneSophie Sejling,

Stephen A. Harrison

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2028395

Subject(s) - semaglutide , medicine , placebo , gastroenterology , nonalcoholic steatohepatitis , fibrosis , surgery , nonalcoholic fatty liver disease , type 2 diabetes , diabetes mellitus , liraglutide , endocrinology , fatty liver , disease , pathology , alternative medicine

Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research